Abstract
Background: Kawasaki disease (KD) is a common cardiovascular disease in infants and young children, with fever, rash, and conjunctivitis as the main clinical manifestations, which can lead to the occurrence of coronary aneurysms. Intravenous immunoglobulin (IVIG) is the preferred treatment for KD patients, but 10–20% of patients are resistant to IVIG. Lipoprotein-associated phospholipase A 2 (Lp-PLA2) is a potential therapeutic target for coronary atherosclerotic heart disease, and the polymorphism of Phospholipase A2 Group VII (PLA2G7) is closely related to the activity of Lp-PLA2, of which rs1051931 is the strongest. Therefore, the rs1051931 polymorphism may be a predictor of IVIG resistance in KD patients.Methods: A total of 760 KD cases, including 148 IVIG-resistant patients and 612 IVIG-responsive patients, were genotyped for rs1051931 in PLA2G7, we compared the effects of rs1051931 on IVIG treatment in KD patients by odds ratios (OR) and 95% confidence interval (CI).Results: The homozygous mutation AA may be a protective factor for IVIG resistance in KD patients (adjusted OR = 3.47, 95% CI = 1.14–10.57, P = 0.0284) and is more evident in patients with KD aged <60 months (adjusted OR = 3.68, 95% CI = 1.10–12.28, P = 0.0399).Conclusions: The PLA2G7 rs1051931 G>A polymorphism may be suitable as a biomarker for the diagnosis or prognosis of IVIG resistance in KD in a southern Chinese population.
Highlights
Kawasaki disease (KD), known as Kawasaki syndrome or mucocutaneous lymph node syndrome, is an acute systemic vasculitis that primarily affects infants and young children [1, 2]
The homozygous mutation AA may be a protective factor for intravenous immunoglobulin (IVIG) resistance in KD patients and is more evident in patients with KD aged
The PLA2G7 rs1051931 G>A polymorphism may be suitable as a biomarker for the diagnosis or prognosis of IVIG resistance in KD in a southern Chinese population
Summary
Kawasaki disease (KD), known as Kawasaki syndrome or mucocutaneous lymph node syndrome, is an acute systemic vasculitis that primarily affects infants and young children [1, 2]. 25% of untreated KD patients developed coronary artery complications [6]. The standard treatment for KD is intravenous immunoglobulin (IVIG), which can reduce both fever duration and the incidence of coronary artery lesions (CAL). Despite receiving IVIG treatment, fever persists in 10–15% of the patients [7], and patients with IVIG resistance have a higher risk of CAL [8]. Kawasaki disease (KD) is a common cardiovascular disease in infants and young children, with fever, rash, and conjunctivitis as the main clinical manifestations, which can lead to the occurrence of coronary aneurysms. Intravenous immunoglobulin (IVIG) is the preferred treatment for KD patients, but 10–20% of patients are resistant to IVIG. The rs1051931 polymorphism may be a predictor of IVIG resistance in KD patients
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
